These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17130405)

  • 1. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward more efficient clinical trials for amyotrophic lateral sclerosis.
    Cudkowicz ME; Katz J; Moore DH; O'Neill G; Glass JD; Mitsumoto H; Appel S; Ravina B; Kieburtz K; Shoulson I; Kaufmann P; Khan J; Simpson E; Shefner J; Levin B; Cwik V; Schoenfeld D; Aggarwal S; McDermott MP; Miller RG
    Amyotroph Lateral Scler; 2010 May; 11(3):259-65. PubMed ID: 19961263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
    Levy G; Kaufmann P; Buchsbaum R; Montes J; Barsdorf A; Arbing R; Battista V; Zhou X; Mitsumoto H; Levin B; Thompson JL
    Neurology; 2006 Mar; 66(5):660-3. PubMed ID: 16534103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we eliminate placebo in ALS clinical Trials?
    Simmons Z
    Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is next in ALS clinical trials?
    Sorenson EJ
    Neurology; 2007 Aug; 69(8):719-20. PubMed ID: 17709702
    [No Abstract]   [Full Text] [Related]  

  • 10. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II/III randomized trial of TCH346 in patients with ALS.
    Miller R; Bradley W; Cudkowicz M; Hubble J; Meininger V; Mitsumoto H; Moore D; Pohlmann H; Sauer D; Silani V; Strong M; Swash M; Vernotica E;
    Neurology; 2007 Aug; 69(8):776-84. PubMed ID: 17709710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cotreatment of amyotrophic lateral sclerosis patients].
    Iwasaki Y; Ikeda K
    Rinsho Shinkeigaku; 1999 Dec; 39(12):1253-5. PubMed ID: 10791091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy development for ALS: lessons learned and path forward.
    Lanka V; Cudkowicz M
    Amyotroph Lateral Scler; 2008 Jun; 9(3):131-40. PubMed ID: 18574756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in ALS: an overview.
    Turner MR; Parton MJ; Leigh PN
    Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
    Ferrante KL; Shefner J; Zhang H; Betensky R; O'Brien M; Yu H; Fantasia M; Taft J; Beal MF; Traynor B; Newhall K; Donofrio P; Caress J; Ashburn C; Freiberg B; O'Neill C; Paladenech C; Walker T; Pestronk A; Abrams B; Florence J; Renna R; Schierbecker J; Malkus B; Cudkowicz M
    Neurology; 2005 Dec; 65(11):1834-6. PubMed ID: 16344537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
    Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.